RAZTAMRI
Dead / Abandoned — Abandoned — no statement of use filed (as of 18 Aug 2025)
What this means for you
This application is over — abandoned 18 Aug 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97855551
- Mark type
- Stylized text
- Filed
- 24 Mar 2023
- Published for opposition
- 03 Dec 2024
- Abandoned
- 18 Aug 2025
- Attorney of record
- Ann Lamport Hammitte
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical products for the treatment of hematologic cancers; pharmaceuticals for treatment of a myelodysplastic syndrome; pharmaceuticals for treatment of acute myeloid leukemia, which is also known as acute myelogenous leukemia and acute nonlymphocytic leukemia
Owner
- SYROS Pharmaceuticals, Inc., Cambridge, MA, US
- SYROS Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 18 Aug 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 18 Aug 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 14 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Dec 2024 — PUBLISHED FOR OPPOSITION
- 27 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 08 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 Nov 2024 — PREVIOUS ALLOWANCE COUNT WITHDRAWN
- 06 Aug 2024 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
- 06 Aug 2024 — PETITION TO DIRECTOR GRANTED
- 02 Aug 2024 — ASSIGNED TO PETITION STAFF
- 22 May 2024 — WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
- 14 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 May 2024 — PUBLISHED FOR OPPOSITION
- 07 May 2024 — TEAS PETITION TO DIRECTOR RECEIVED